Welcome to our dedicated page for Phibro Animal Health news (Ticker: PAHC), a resource for investors and traders seeking the latest updates and insights on Phibro Animal Health stock.
Phibro Animal Health Corporation reports developments in animal health, mineral nutrition and performance products for food-animal markets. The company develops, manufactures and markets antibacterials, anticoccidials, nutritional specialty products, vaccines and mineral nutrition products for poultry, swine, beef and dairy cattle, and aquaculture in the United States and international markets.
Recurring PAHC news includes quarterly results and guidance, cash dividend declarations on Class A and Class B common stock, investor conference participation and regulatory updates affecting antimicrobial products such as virginiamycin and bacitracin. Company updates also address product portfolio activity, acquisition-related effects, input and distribution costs, foreign-currency impacts and tools such as PhibroVet for veterinary prescription management.
Phibro Animal Health (Nasdaq: PAHC) announced on October 9, 2025 an exclusive licensing agreement with Lighthouse Pharmaceuticals to develop, manufacture, and commercialize a proprietary compound for canine periodontal health. Phibro will lead global regulatory, commercial, and distribution efforts while Lighthouse advances its gingipain inhibitor platform. The compound has shown preclinical efficacy and safety. Financial terms were not disclosed. The collaboration targets improved veterinary periodontal care and potential long‑term benefits for dogs and companion animal portfolios.
Phibro Animal Health Corporation (Nasdaq: PAHC) announced its participation in the upcoming Morgan Stanley Annual Global Healthcare Conference. CFO Glenn David will present to financial analysts and investors on September 9, 2025, at 12:20 PM ET at the Sheraton New York Times Square Hotel.
The presentation will be accessible via live audio stream on the company's investor relations website, with a replay available for later viewing.
Phibro Animal Health (NASDAQ:PAHC) reported strong financial results for Q4 and fiscal year 2025, with significant growth across key metrics. The company achieved Q4 net sales of $378.7M (up 39%) and net income of $17.2M (up $16.5M), with diluted EPS of $0.42.
For FY2025, PAHC reported net sales of $1.29B (up 27%), net income of $48.3M, and adjusted EBITDA of $183.7M (up 65%). The growth was primarily driven by the successful integration of the Zoetis MFA portfolio and strong performance across Animal Health segments.
Looking ahead, PAHC provided FY2026 guidance with projected net sales of $1.43-1.48B and adjusted EBITDA of $225-235M, reflecting continued confidence in their growth trajectory.
Phibro Animal Health Corporation (Nasdaq: PAHC) has scheduled its fourth quarter and fiscal year 2025 financial results announcement for Wednesday, August 27, 2025, after market close. The company will host a conference call and webcast to discuss the results on Thursday, August 28, 2025, at 9:00 AM Eastern Time.
Investors can access the presentation through the company's investor relations website at https://investors.pahc.com or join via phone using the provided dial-in numbers. A replay of the webcast will be made available approximately two hours after the event concludes.
Phibro Animal Health Corporation (Nasdaq: PAHC) has announced a quarterly dividend declaration. The company's Board of Directors has approved a cash dividend of $0.12 per share for both Class A and Class B common stock. The dividend will be paid on September 24, 2025, to shareholders who are registered as of September 3, 2025.
Phibro Animal Health Corporation (NASDAQ: PAHC) has announced its participation in the upcoming Stifel Jaws & Paws Conference. The company's Chief Operating Officer Larry Miller and Director and Executive Vice President of Corporate Strategy Daniel Bendheim will present to financial analysts and investors on Thursday, May 29, 2025, at 8:35 AM ET at the Lotte New York Hotel. The presentation will be accessible via live audio stream on Phibro's investor relations website, with a replay available for later viewing.
Phibro Animal Health Corporation (NASDAQ: PAHC) has announced a quarterly cash dividend declaration. The company's Board of Directors has approved a dividend payment of $0.12 per share for both Class A and Class B common stock. The dividend will be paid on June 25, 2025, to stockholders who are registered as of the close of business on June 4, 2025.
Phibro Animal Health (Nasdaq: PAHC) has scheduled its third quarter financial results announcement for Wednesday, May 7, 2025, after market close. The company will hold a conference call and webcast to discuss the results on Thursday, May 8, 2025, at 9:00 AM Eastern Time.
Investors can access the presentation slides and webcast through https://investors.pahc.com. The conference call will be available via phone at +1 (888) 330-2022 for U.S. and Canada callers, or +1 (365) 977-0051 for international participants, using conference ID 3927884. A replay of the webcast will be made available approximately two hours after the event concludes.
Phibro Animal Health (Nasdaq: PAHC) has announced its participation in the upcoming Barclays Annual Global Healthcare Conference. Chief Financial Officer Glenn David will present to financial analysts and investors on Thursday, March 13, 2025, at 9:00 AM ET at the Loews Miami Beach Hotel.
The presentation will be accessible through a live audio stream on the company's investor relations website at https://investors.pahc.com. For those unable to attend, a replay of the session will be made available and archived on the same platform.